Pfizer CEO: Allergan deal is ‘a lot more about growth’ than job cuts

Carly Helfand

Anyone who's examined 's job-chopping track record knows the company has a tendency to wield the ax in the wake of a megamerger. But this time? Things will be different, CEO Ian Read said of 's tie-up on Tuesday at the J.P. Morgan Healthcare Conference.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2019 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS